Omada Health (NASDAQ:OMDA – Free Report) had its target price lowered by JPMorgan Chase & Co. from $30.00 to $25.00 in a report released on Monday morning,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock.
OMDA has been the topic of a number of other reports. Weiss Ratings upgraded Omada Health from a “sell (d)” rating to a “sell (d+)” rating in a report on Monday, November 9th. Robert W. Baird upped their price objective on Omada Health from $15.00 to $25.00 and gave the company a “neutral” rating in a research note on Wednesday, August 12th. Zacks Research downgraded Omada Health from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 4th. BMO Capital Markets reaffirmed an “outperform” rating and set a $24.00 target price on shares of Omada Health in a research report on Friday, August 7th. Finally, Canaccord Genuity Group lifted their target price on Omada Health from $24.00 to $28.00 and gave the stock a “buy” rating in a research note on Tuesday, July 21st. Eleven equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Omada Health presently has an average rating of “Moderate Buy” and an average price target of $25.92.
Get Our Latest Research Report on Omada Health
Omada Health Stock Down 6.5%
Omada Health (NASDAQ:OMDA – Get Free Report) last released its earnings results on Thursday, November 5th. The company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.08. The company had revenue of $91.31 million during the quarter. Omada Health had a return on equity of 5.71% and a net margin of 4.21%. On average, equities analysts anticipate that Omada Health will post 0.09 EPS for the current year.
Insider Buying and Selling at Omada Health
In other news, CEO Sean P. Duffy sold 21,572 shares of the firm’s stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $23.62, for a total transaction of $509,530.64. Following the completion of the sale, the chief executive officer owned 411,861 shares in the company, valued at $9,728,156.82. This trade represents a 4.98% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Steven L. Cook sold 6,800 shares of Omada Health stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $21.86, for a total transaction of $148,648.00. Following the completion of the sale, the chief financial officer directly owned 173,906 shares in the company, valued at $3,801,585.16. This trade represents a 3.76% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 79,322 shares of company stock worth $1,720,914 over the last three months. 6.38% of the stock is currently owned by insiders.
Hedge Funds Weigh In On Omada Health
Several institutional investors have recently bought and sold shares of OMDA. Sterling Capital Management LLC increased its position in Omada Health by 1,161.6% in the third quarter. Sterling Capital Management LLC now owns 1,577 shares of the company’s stock worth $33,000 after buying an additional 1,452 shares during the last quarter. Integrated Wealth Concepts LLC purchased a new position in shares of Omada Health during the 2nd quarter valued at $53,000. State of Alaska Department of Revenue purchased a new position in shares of Omada Health during the 3rd quarter valued at $59,000. Versant Capital Management Inc lifted its position in shares of Omada Health by 319.3% during the 2nd quarter. Versant Capital Management Inc now owns 2,998 shares of the company’s stock valued at $66,000 after buying an additional 2,283 shares during the last quarter. Finally, Legal & General Group Plc bought a new position in shares of Omada Health during the 2nd quarter worth $76,000.
Omada Health Company Profile
Omada Health is a U.S. digital health company that provides virtual care programs for people managing chronic conditions. Its services address areas including diabetes, prediabetes, hypertension, musculoskeletal conditions and weight management. The company combines digital tools, personalized health coaching and, where appropriate, clinical support to help members build health habits and manage their care. Programs may include mobile-app-based guidance and connected devices, such as scales or blood pressure monitors.
Recommended Stories
- Five stocks we like better than Omada Health
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Omada Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omada Health and related companies with MarketBeat.com's FREE daily email newsletter.
